A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

Among patients with psoriasis who have active or recent cancer, biologic therapies show similar cancer progression or recurrence and serious infection rates compared with conventional systemic agents.

Sino Biopharmaceutical ( ($HK:1177) ) has provided an update. Sino Biopharmaceutical has reported positive Phase II clinical trial results for ...

PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

Livzon Pharmaceutical Group ( ($HK:1513) ) just unveiled an update. Livzon MABPharm has had its marketing authorization application for Lecankitug ...

The ustekinumab (Stelara; Janssen Biotech) biosimilar DMB-3115 (Imuldosa; Accord BioPharma) demonstrated clinical efficacy and safety comparable to the reference product through 52 weeks in a recent ...

In this MedPage Today video segment, Linda Stein Gold, MD, director of dermatology clinical research at the Henry Ford Health System in Detroit, discusses the promise of TYK2 inhibitors and an oral ...